From: Oral hypoglycemic agents: do the ends justify the means?
 | Castillo et al. [11] | Cheng et al. [12] | ||||
---|---|---|---|---|---|---|
 | Glyburide | Insulin | R.R 95 % C.I. | Glyburide | Insulin | O.R. 95 % C.I. |
 | N = 4982 | N = 4191 |  | N = 2073 | N = 8604 |  |
LGA | 4.7Â % | 3.2Â % | 1.43 (1.16-1.76) | 17.6Â % | 19.0Â % | 1.03 (0.83-1.20) |
Macrosomia | n.a. | n.a. | --- | 13.4Â % | 13.1Â % | 1.29 (1.03-1.64) |
Hypoglycemia | 1.9Â % | 1.3Â % | 1.40 (1.00-1.95) | n.a. | n.a. | --- |
Jaundice | 0.3Â % | 0.4Â % | 0.96 (0.48-1.91) | n.a. | n.a. | --- |
Neonatal RDS | 2.9Â % | 1.7Â % | 1.63 (1.23-2.15) | n.a. | n.a. | --- |
Preterm | 9.5Â % | 8.9Â % | 1.06 (0.93-1.00) | n.a. | n.a. | --- |
NICU admission | 10.2Â % | 7.2Â % | 1.41 (1.23-1.62) | 8.1Â % | 6.5Â % | 1.32 (1.07-2.00) |
Birth injury | 2.2Â % | 1.6Â % | 1.35 (1.00-1.82 | n.a. | n.a | --- |
Cesarean delivery | 50.6Â % | 52.5Â % | 0.97 (0.93-1.00) | 38.8Â % | 44.9Â % | 0.77 (0.65-0.91) |